soul trial oral semaglutide cardiovascular outcomes 2024 results nejm SOUL: Bests Usual Care in High-Risk Type 2 Diabetes SOUL (Semaglutide cardiOvascular oUtcomes triaL)

For patients and healthcare providers, the appeal is clear: retatrutide may finally address the full spectrum of metabolic dysfunctionfrom obesity and diabetes to fatty liver diseaseoffering a treatment option that is both broader in scope and more powerful in effect

Semaglutide is the established GLP-1 receptor agonist with three FDA approvals and the most comprehensive clinical evidence base in its class

Additional research will be required to determine how these attributes may translate into clinical practice

This mechanism promotes sustainable weight loss, improves insulin resistance, and contributes to the reduction of cardiometabolic risks

[DOI] [PubMed] [Google Scholar] 20.Kumar A., et al